Autism Diagnostics Market Size & Share, by Type (Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder); Drug Class (Serotonin Uptake Inhibitors, Insomnia Drugs, Anticonvulsants, Antipsychotics); Treatment Type (Communication and Behavioural Therapy, Hyperbaric Oxygen Therapy, Chelation Therapy, Oxytocin Therapy, Drug Therapies); Distribution Channel (Hospital, Retail & Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5382
  • Published Date: Nov 20, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Autism Diagnostics Market size is expected to cross USD 5.4 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of autism diagnostics was over USD 2 Billion. The growth of the market for autism diagnostics is growing due to advances in biotechnology and increased access to healthcare facilities worldwide. For example, the American Medical Association (AMA) reports that in 2020, U.S. health spending climbed by 9.7% to USD 4.1 trillion, or USD 12,530 per capita.

In addition, manufacturing processes slowed down as a result of some healthcare organizations closing their doors in the early phases of the extraordinary epidemic. Furthermore, the cessation or postponing of therapy sessions for children with autism was caused by the closing of therapy centers and services connected to autism disorders. Nonetheless, telemedicine solutions have been widely adopted by patient caretakers and families due to the rising anxiety levels of autistic patients and their increased vulnerability to COVID-19. This element also raised the market for therapies and other prescription off-label treatments like SSRIs, antipsychotics, and sleep aids. Moreover, a further factor in the market's expansion during COVID-19 was the rise in the use of internet channels to purchase autism drugs.

Get more information on this report: Request Free Sample PDF

Autism Diagnostics Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Autism Prevalence to Drive Market Expansion - Global market growth is being positively impacted by an increase in the prevalence of autism, which has raised the need for clinical research to find effective treatments. This can lead to better patient outcomes and increase therapy accuracy for various ailments. According to the Centers for Disease Control and Prevention most recent data from 2023, one in every 36 children has an autistic diagnosis at this time.
  • Governmental Efforts on Raising Autism Awareness to Accelerate Market Development - The autism diagnostics market is growing as a result of an increasing number of government initiatives, such as the creation of different foundations and the approval of various financing sources for autism awareness initiatives in various nations. The Saskatchewan government has been involved in a number of global programmes aimed at raising awareness of autism. The Saskatchewan government declared in July 2021 that families whose children have been diagnosed with the illness will get more funding. For children aged eleven, Autism Individualised funding will be available as of July 27, 2021. Children who were born on March 31, 2021, or earlier, were qualified to apply for the last pay-out. Additionally, USD 10.3 million was allocated in 2021–2022 to give USD 6,000.0 per year to children with ASD who are between the ages of 6 and 11.
  • Greater Research on Enzyme Replacement Therapy as a New Autism Treatment - Numerous treatments were created, but owing to certain issues, they had to be stopped. At that point, enzyme replacement therapy as one of the most significant developments in the treatment of autistic disorder was presented. Researchers from all over the world think that the extra opioid activity in the brain that causes autism is what causes the digestive issues linked to specific proteins in food. For example, Curemark created CM-AT, a medication that the FDA designated as being on the "Fast Track" for children with autism who had abnormally low levels of chymotrypsin. This enzyme is necessary for the body's inability to produce certain amino acids from food protein. Enzyme replacement therapy is proving to be an effective innovative therapy for treating this condition because of its many favourable outcomes.


  • Absence of Licenced Medicines Will Limit Market Expansion - Despite the growing demand for efficient medications and autism clinical trials, there is currently no treatment that may cure autism spectrum disease or any of the primary symptoms that are linked with it. Clinical translation research has been shown to have methodological flaws, gaps in knowledge, and conceptual paradigms. Despite several attempts, there is no solid proof that any medication is effective in treating the basic symptoms of the disorder in the age of focused therapy. As a result, it presents a difficulty for the development of treatments, which reduces the need for therapies for autism spectrum disorders.
  • One of the main issues that is anticipated to impede the market for autism diagnosis and therapies is the lack of specialists with the training and experience necessary to properly diagnose autism.
  • The primary obstacle to the market's expansion is the high expense of diagnosing and treating autism spectrum disorder.

Autism Diagnostics Market: Key Insights

Base Year


Forecast Year



~ 8%

Base Year Market Size (2023)

 ~ USD 2 Billion

Forecast Year Market Size (2036)

 ~ USD 5.4 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Autism Diagnostics Segmentation

Type (Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder)

The autistic disorders segment is predicted to hold 50% share of the global autism diagnostics market by 2036. This is due to initiatives done by the government and industry participants, as well as factors like increased research and development. In addition to having an intellectual handicap, people with autism disorder typically experience severe language delays, social and communication difficulties, strange behaviours, and peculiar hobbies. The percentage of American children with autism has increased from 1 in 44 to 1 in 36. In the United States, 1 in 100 girls and 4 in 100 boys are autistic. In the United States, 1 in 100 girls and 4 in 100 boys are autistic. Compared to girls, boys have a nearly 4-fold higher diagnosis rate for autism.

Drug Class (Serotonin Uptake Inhibitors, Insomnia Drugs, Anticonvulsants, Antipsychotics)

Autism diagnostics market from the antipsychotics segment is attributed to hold largest revenue share of about 40% during the forecast period. Antipsychotic medications are now widely available and are the safest and most successful treatment for individuals with autism, which explains this development. The only drugs currently licenced by the FDA to treat irritability in kids with autism spectrum conditions are Abilify and Risperdal. Patients with autism typically utilise these medications because of their superior safety, effectiveness, and tolerability compared to other medications.

Our in-depth analysis of the global autism diagnostics market includes the following segments:


  • Autistic Disorder
  • Asperger Syndrome
  • Childhood Disintegrative Disorder

Drug Class

  • Serotonin Uptake Inhibitors
  • Insomnia Drugs
  • Anticonvulsants
  • Antipsychotics

Treatment Type

  • Communication and Behavioural Therapy
  • Hyperbaric Oxygen Therapy
  • Chelation Therapy
  • Oxytocin Therapy
  • Drug Therapies

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Autism Diagnostics Industry - Regional Synopsis

North America Market Forecast

Autism diagnostics market in North America region is anticipated to hold largest revenue share of about 30% by the end of 2036. The growth of the market in this region is due to the introduction and quick adoption of several autism medications. It is anticipated that the region's increased ASD research activity is expected to create new growth prospects. The United States has maintained a sizable market share in North America. The prevalence of autism spectrum diseases, rising R&D costs, and an increase in investment volume are the main drivers of market expansion. For example, according to a Centres for Disease Control and Prevention (CDC) update from March 2022, around 1 in 44 children has been diagnosed with autism spectrum disorder (ASD). As a result, the nation's need for treatment for autism spectrum disorders is rising. For example, F. Hoffmann-La Roche Ltd. started a clinical trial research in January 2020 in Toronto, Canada, for individuals with autism using the novel investigational medication Balovaptan. It is anticipated that the study's successful conclusion will stimulate market expansion.

Europe Market Statistics

Europe autism diagnostics market is expected to hold 27% of the revenue share by 2036, owing to the rising R&D activity and a growing public awareness of autism. The growth of the market in this region is because of increased awareness and screening, easier access to assistance, and broader diagnostic criteria. Moreover, it is projected that throughout the projection period, increased product sales will strengthen the market in the area.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Autism Diagnostics Landscape

    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • Curemark LLC
    • Yamo Pharmaceuticals, LLC
    • Merck & Co Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Johnson & Johnson Services, Inc.
    • Bristol-Myer Squibb
    • Janssen Pharmaceuticals, Inc.
    • Axial Therapeutics, Inc.

In the News

  • Novartis AG announced collaboration with Sangamo to research gene therapies for the treatment of autism spectrum disease. The top two brands will partner to develop gene therapies and other brain problems for ASD treatments. The agreement between Novartis and Sangamo provided the Brisbane-based firm with a net worth of approximately USD 75 million to accomplish the milestones in its commercial development.
  • Axial Therapeutics announced that the company received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for their lead candidate named AB-2004, which is a gut targeted, molecular therapeutic being studied for the treatment of irritability associated with ASD.

Author Credits:  Radhika Pawar

  • Report ID: 5382
  • Published Date: Nov 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing government efforts on raising funds and awareness for autism as well as increasing research and development are the major factors driving the growth of the autism diagnostics market.

The market size of autism diagnostics is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market are Novartis AG, Allergan, Merck & Co Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Bristol-Myer Squibb, Janssen Pharmaceuticals, Inc., and others.

The autistic disorder segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Autism Diagnostics Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying